Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib in Advanced Malignant Pleural Mesothelioma
NCT01769547Phase 2Terminated
- Sponsor
- Ontario Clinical Oncology Group
- Start
- Mar 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dovitinib in malignant pleural mesothelioma (MPM), sponsored by Ontario Clinical Oncology Group. Started Mar 2013; status: terminated.
02
Drugs
dovitinib
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT01769547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01769547.